Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010.
Loko MA, Salmon D, Carrieri P, Winnock M, Mora M, Merchadou L, Gillet S, Pambrun E, Delaune J, Valantin MA, Poizot-Martin I, Neau D, Bonnard P, Rosenthal E, Barange K, Morlat P, Lacombe K, Gervais A, Rouges F, See AB, Lascoux-Combe C, Vittecoq D, Goujard C, Duvivier C, Spire B, Izopet J, Sogni P, Serfaty L, Benhamou Y, Bani-Sadr F, Dabis F; ANRS CO 13 HEPAVIH Study Group. Loko MA, et al. Among authors: vittecoq d. BMC Infect Dis. 2010 Oct 22;10:303. doi: 10.1186/1471-2334-10-303. BMC Infect Dis. 2010. PMID: 20969743 Free PMC article.
Urolithiasis in HIV-positive patients treated with atazanavir.
Couzigou C, Daudon M, Meynard JL, Borsa-Lebas F, Higueret D, Escaut L, Zucman D, Liotier JY, Quencez JL, Asselah K, May T, Neau D, Vittecoq D. Couzigou C, et al. Among authors: vittecoq d. Clin Infect Dis. 2007 Oct 15;45(8):e105-8. doi: 10.1086/521930. Epub 2007 Sep 12. Clin Infect Dis. 2007. PMID: 17879904
Preservation of immune function and anti-hepatitis C virus (HCV) immune responses after liver transplantation in HIV-HCV coinfected patients (ANRS-HC08 "THEVIC" trial).
Samri A, Roque-Afonso AM, Beran O, Tateo M, Teicher E, Feray C, Sebagh M, Guettier C, Dussaix E, Vittecoq D, Samuel D, Autran B, Duclos-Vallée JC. Samri A, et al. Among authors: vittecoq d. J Hepatol. 2009 Dec;51(6):1000-9. doi: 10.1016/j.jhep.2009.06.031. Epub 2009 Sep 12. J Hepatol. 2009. PMID: 19833404 Clinical Trial.
Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial.
Bouldouyre MA, Charreau I, Marchou B, Tangre P, Katlama C, Morlat P, Meiffredy V, Vittecoq D, Bierling P, Aboulker JP, Molina JM; ANRS 106 Study Group. Bouldouyre MA, et al. Among authors: vittecoq d. J Acquir Immune Defic Syndr. 2009 Dec;52(5):531-7. doi: 10.1097/QAI.0b013e3181be73e3. J Acquir Immune Defic Syndr. 2009. PMID: 19855285 Clinical Trial.
Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH.
Salmon D, Bani-Sadr F, Loko MA, Stitou H, Gervais A, Durant J, Rosenthal E, Quertainmont Y, Barange K, Vittecoq D, Shoai-Tehrani M, Alvarez M, Winnock M, Trinchet JC, Dabis F, Sogni P. Salmon D, et al. Among authors: vittecoq d. J Hepatol. 2012 Apr;56(4):862-8. doi: 10.1016/j.jhep.2011.11.009. Epub 2011 Dec 13. J Hepatol. 2012. PMID: 22173166
Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.
Fagard C, Colin C, Charpentier C, Rami A, Jacomet C, Yeni P, Vittecoq D, Katlama C, Molina JM, Descamps D, Chêne G, Yazdanpanah Y; ANRS 139 TRIO Trial Group. Fagard C, et al. Among authors: vittecoq d. J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):489-93. doi: 10.1097/QAI.0b013e31824bb720. J Acquir Immune Defic Syndr. 2012. PMID: 22293546
Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
Loko MA, Bani-Sadr F, Valantin MA, Lascoux-Combe C, Fontaine H, Bonnard P, Gervais A, Bouchaud O, Garipuy D, Quertainmont Y, Vittecoq D, Tehrani MS, Winnock M, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group. Loko MA, et al. Among authors: vittecoq d. Antivir Ther. 2012;17(7):1335-43. doi: 10.3851/IMP2419. Epub 2012 Oct 10. Antivir Ther. 2012. PMID: 23052829
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.
Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, Poizot-Martin I, Richmond G, Soriano V, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J; VIKING Study Group. Eron JJ, et al. J Infect Dis. 2013 Mar 1;207(5):740-8. doi: 10.1093/infdis/jis750. Epub 2012 Dec 7. J Infect Dis. 2013. PMID: 23225901 Free PMC article. Clinical Trial.
286 results